Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01093 CSPC PHARMA
RTNominal down6.150 -0.120 (-1.914%)
Others

02/01/2020 17:52

CSPC Pharma (01093) gets drug registration approval

[ET Net News Agency, 2 January 2020] CSPC Pharmaceutical Group Limited (01093) said
"Sunitinib Malate Capsules (12.5mg)" developed by CSPC Ouyi Pharmaceutical Co., Ltd., a
subsidiary of the company, has been granted drug registration approval by the National
Medical Products Administration of the People's Republic of China, being the first generic
drug of this type approved in China.
Sunitinib Malate is an oncology drug indicated for the treatment of 1) inoperable
advanced renal cell carcinoma (RCC); 2) gastrointestinal stromal tumour (GIST) after
failure of or intolerance to imatinib mesylate treatment; and 3) progressive,
well-differentiated pancreatic neuroendocrine tumour (pNET) in adult patients with
unresectable or metastatic disease. (RC)

Remark: Real time quote last updated: 28/03/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.